- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01056471
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
August 4, 2015 updated by: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Multicenter Clinical Trial Phase I / II Randomized, Placebo-controlled Study to Evaluate Safety and Feasibility of Therapy With Two Different Doses of Autologous Mesenchymal Stem Cells in Patients With Secondary Progressive Multiple Sclerosis Who do Not Respond to Treatment
The main purpose of this study is to evaluate the safety and feasibility of regenerative therapy with mesenchymal stem cells from adipose tissue, administered intravenously in patients with secondary progressive multiple sclerosis who do not respond to treatment.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Málaga, Spain, 29010
- Hospital Regional Universitario de Malaga
-
Sevilla, Spain, 41004
- Hospital Universitario Virgen Macarena
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients diagnosed with Multiple Sclerosis (Poser and McDonald criteria).
- Secondary progressive MS patients with EDSS ≥ 5.5 and ≤ 9.
- Patients with treatment failure defined by: no response to immunomodulators / immunosuppressants, and showing activity in the form of 1 relapse in the last year or 0.5 points in EDSS progression.
- Patients with no MS relapse and no steroid treatment within the month prior to inclusion.
- Patients who give written consent to participate in the study. -
Exclusion Criteria:
- History of current pathology or current laboratory results indicative of any severe disease.
- Pacemaker or metallic implants that prevent MR imaging.
- Inability to complete questionnaires.
- Refusal to give informed consent.
- Predicted impossibility for a biopsy of at least 30 grams of fat tissue.
- Positive screening test for HIV, Hepatitis B or Hepatitis C.
- History of malignancy.
- Having been in treatment with any investigational drug or have undergone any experimental procedure in the 3 months prior to baseline.
- Body mass index> 40 kg/m2.
- Patients who have been treated with prohibited concomitant medication during the month prior to inclusion in the study.
Pregnancy or lactation
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose autologous mesenchymal cells
The dose of infused cells is 10e6 cells/Kg
|
Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
Intravenous infusion of autologous mesenchymal stem cells.
Dose: 10e6 cells/Kg.
|
Experimental: High dose
The dose of infused cells is 4*10e6 cells/Kg
|
Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
Intravenous infusion of autologous mesenchymal stem cells.
Dose: 10e6 cells/Kg.
|
No Intervention: Placebo Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells
Time Frame: 12 months.
|
12 months.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Oscar Fernandez Fernandez, MD, PhD, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
- Principal Investigator: Guillermo Izquierdo Ayuso, MD, PhD, Hospital Universitario Virgen Macarena, Sevilla, Spain
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
June 1, 2015
Study Registration Dates
First Submitted
January 25, 2010
First Submitted That Met QC Criteria
January 25, 2010
First Posted (Estimate)
January 26, 2010
Study Record Updates
Last Update Posted (Estimate)
August 7, 2015
Last Update Submitted That Met QC Criteria
August 4, 2015
Last Verified
February 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Leukoencephalopathies
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Nervous System Diseases
- Autoimmune Diseases
- Demyelinating Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Autoimmune Diseases, CNS
- Immune System Diseases
Other Study ID Numbers
- CMM/EM/2008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nervous System Diseases
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
University of MichiganCompletedAutonomic Peripheral Nervous System DiseasesUnited States
-
Washington University School of MedicineRecruitingCentral Nervous SystemUnited States
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
Clinical Trials on Autologous mesenchymal stem cells from adipose tissue.
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Bukwang PharmaceuticalCompletedSpinal Cord InjuryKorea, Republic of
-
R-BioKyung Hee University Hospital at GangdongCompletedCerebral PalsyKorea, Republic of
-
R-BioCompletedBuerger's DiseaseKorea, Republic of
-
Celal Bayar UniversityThe Scientific and Technological Research Council of Turkey; Acıbadem LabcellCompletedSkin Diseases | Immune System Diseases | Autoimmune Diseases | UrticariaTurkey
-
Rigshospitalet, DenmarkCompletedDry Eye | Kerato Conjunctivitis Sicca | Aqueous Tear DeficiencyDenmark
-
Mohamad BydonCompletedParalysis | Spinal Cord InjuriesUnited States
-
The Foundation for Orthopaedics and Regenerative...SuspendedSpinal Cord InjuriesGreece
-
National Yang Ming UniversityCompletedThe Sequelae Caused by Severe Brain InjuryTaiwan
-
The Foundation for Orthopaedics and Regenerative...Suspended